EUVIMEDEUVIMED entdecken
Crossref

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Jonathan Barratt, Robert M Brenner, Sean J Barbour, Kirk N Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W Fordyce, Vivekanand Jha iD, Zeeshan Khawaja, Beom Seok Kim iD, Adrian Liew und 13 weitere

New England Journal of Medicine · 22.10.2026

DOI: 10.1056/nejmoa2610103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 22.10.2026. Verfasst von Jonathan Barratt und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Leicester, Leicester, United Kingdom. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Vera Therapeutics, Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • University of Leicester, Leicester, United Kingdom.
  • Vera Therapeutics, Brisbane, CA.
  • Division of Nephrology, University of British Columbia, Vancouver, Canada.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Faculty of Medicine, Division of Nephrology, Kocaeli University, Kocaeli, Turkey.
  • Departments of Nephrology and Cardiology, RWTH Aachen University Hospital, Aachen, Germany.

ORCID-Profile: Vivekanand Jha, Beom Seok Kim

Förderung

  • Vera Therapeutics, Inc.

Zitieren

APA

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits-Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., …, & ORIGIN Phase 3 Trial Investigators (2026). Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103

Vancouver

Barratt J, Brenner RM, Barbour SJ, Campbell KN, Doan T, Eren N, et al. Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2610103

BibTeX
@article{Barratt2026,
  author = {Barratt, Jonathan and Brenner, Robert M and Barbour, Sean J and Campbell, Kirk N and Doan, Tom and Eren, Necmi and Floege, Jürgen and Fordyce, Marshall W and Jha, Vivekanand and Khawaja, Zeeshan and Kim, Beom Seok and Liew, Adrian and Maes, Bart and Pal, Atanu and Pecoits-Filho, Roberto and Phoon, Richard K S and Rizk, Dana V and Suzuki, Hitoshi and Tesař, Vladimír and Trimarchi, Hernán and Wei, Xuelian and Yu, Lixi and Zhang, Hong and Lafayette, Richard and ORIGIN Phase 3 Trial Investigators, ORIGIN Phase 3 Trial Investigators},
  title = {Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2610103}
}
Kostenlos starten →